Home > Pulmonology > ERS 2020 > Chronic Cough – State of the Art > First-in-class P2X3 receptor antagonist shows promise for chronic cough treatment

First-in-class P2X3 receptor antagonist shows promise for chronic cough treatment

Presented By
Prof. Lorcan McGarvey , Queen's University Belfast
Conference
ERS 2020
Trial
Phase 3, COUGH-1, COUGH-2
  In two phase 3 studies, the P2X3 receptor antagonist gefapixant not only reduced the frequency of cough in patients with refractory or unexplained cough but also increased their quality of life [1]. COUGH-1 and COUGH-2 are 2 randomised, placebo-controlled, double-blind studies in parallel design, testing the efficacy of gefapixant in adults without substantial abnormalities in their chest x-ray, suffering ≥1 years from refractory or unexplained chronic cough. The 2 studies included just over 2,000 patients for treatment with gefapixant 45 mg twice daily, or 15 mg twice daily, or placebo over 12 (COUGH-1) and 24 (COUGH-2) weeks. Primary endpoints were objectively measured 24-h cough frequency as well as safety and tolerability. Secondary endpoints incl...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on